SCHEMBL5540929

SCHEMBL5540929

Cc1cccc(N2CCC(OC=O)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.51
GPR119 Q8TDV5 1/20 0.50
ADRB1 P08588 1/20 0.50
FFAR4 Q5NUL3 1/20 0.47
KCNH2 Q12809 2/20 0.46
ACACB O00763 2/20 0.45
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPY5R Q15761 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
C1S P09871 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27918380 0.84 HTR3E (0.51) NOTUMADRB1KCNH2ALDH1A1MAPT
SCHEMBL12093607 0.81 ADRB1 (0.56) NOTUMGPR119ADRB1FFAR4KCNH2
SCHEMBL5540472 0.81 MAPT (0.47) GPR119ADRB1ALDH1A1MAPTRAB9A
SCHEMBL5536223 0.81 MBTD1 (0.47) NOTUMGPR119ADRB1FFAR4ALDH1A1
SCHEMBL23803729 0.80 NOTUM (0.55) NOTUMGPR119ADRB1FFAR4KCNH2
SCHEMBL5539231 0.80 NOTUM (0.55) NOTUMACACBALDH1A1MAPTRAB9A
SCHEMBL5536949 0.80 L3MBTL3 (0.43) KCNH2L3MBTL1
SCHEMBL5540924 0.79 NOTUM (0.51) NOTUMGPR119ADRB1FFAR4KCNH2
SCHEMBL5541996 0.78 NOTUM (0.44) NOTUMACACBALDH1A1MAPTRAB9A
SCHEMBL5538573 0.77 ALDH1A1 (0.46) ALDH1A1MAPTMEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOTUM 3827/4885GPR119 658/4885ADRB1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.